Soluble mesothelin-related peptides levels in patients with malignant mesothelioma

Disease Markers

Volumn 32, Issue 2, 2012, Pages 123-131

  Franko, Alenka ^a   Dolzan, Vita ^b   Kovac, Viljem ^c   Arneric, Niko ^a   Dodic Fikfak, Metoda ^a  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

^c INSTITUTE OF ONCOLOGY   (Slovenia)

Author keywords

Asbestos exposure; Malignant mesothelioma; Soluble Mesothelin Related Peptides (SMRP); Tumor marker; Tumor response to treatment

Indexed keywords

MONOCLONAL ANTIBODY; SOLUBLE MESOTHELIN RELATED PEPTIDE; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER PROGNOSIS; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SOLUBLE MESOTHELIN RELATED PEPTIDE BLOOD LEVEL; TREATMENT RESPONSE;

EID: 84858187904     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.3233/DMA-2011-0866     Document Type: Article

References (49)

1. B.W. Robinson and R.A. Lake, Advances in malignant mesothelioma, N Engl J Med 353 (2005), 1591-1603. (Pubitemid 41434638)
2. J.E. King and P.S. Hasleton, The epidemiology and aetiology of malignant mesothelioma, in: Malignant Pleural Mesothe-lioma, K. O'Byrne and V. Rusch, eds, Oxford University Press, Oxford, New York, 2006, pp. 1-18.
3. J.C. Wagner, C.A. Sleggs and P. Marchand, Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province, Br J Ind Med 17 (1960), 260-271.
4. A. Agudo, C.A. Gonzalez, M.J. Bleda, J. Ramirez, S. Hernandez, F. Lopez, A. Calleja, R. Panades, D. Turuguet, A. Escolar, M. Beltran and J.E. Gonzalez-Moya, Occupation and risk of malignant pleural mesothelioma: A case-control study in Spain, Am J Ind Med 37 (2000), 159-168. (Pubitemid 30036726)
5. D. Howel, A. Gibbs, L. Arblaster, L. Swinburne, M. Schweiger, E. Renvoize, P. Hatton and F. Pooley, Mineral fibre analysis and routes of exposure to asbestos in the development of mesothelioma in an English region, Occup Environ Med 56 (1999), 51-58. (Pubitemid 29103649)
6. Y. Iwatsubo, J.C. Pairon, C. Boutin, O. Menard, N. Massin, D. Caillaud, E. Orlowski, F. Galateau-Salle, J. Bignon and P. Brochard, Pleural mesothelioma: dose-response relation at low levels of asbestos exposure in a French population-based case-control study, Am J Epidemiol 148 (1998), 133-142. (Pubitemid 128721148)
7. L. Zellos and D.C. Christiani, Epidemiology, biologic behavior, and natural history of mesothelioma, Thorac Surg Clin 14 (2004), 469-477, viii. (Pubitemid 39314480)
8. R.P. Abratt, D.A. Vorobiof and N. White, Asbestos and mesothelioma in South Africa, Lung Cancer 45(SUPPL 1) (2004), S3-S6. (Pubitemid 38917105)
9. M. Berry, Mesothelioma incidence and community asbestos exposure, Environ Res 75 (1997), 34-40. (Pubitemid 27446793)
10. R. Hassan and M. Ho, Mesothelin targeted cancer im-munotherapy, Eur J Cancer 44 (2008), 46-53.
11. C. Magnani, P. Dalmasso, A. Biggeri, C. Ivaldi, D. Mirabelli and B. Terracini, Increased risk of malignant mesothelioma of the pleura after residential or domestic exposure to asbestos: a case-control study in Casale Monferrato, Italy, Environ Health Perspect 109 (2001), 915-919. (Pubitemid 32976256)
12. M.M. Maule, C. Magnani, P. Dalmasso, D. Mirabelli, F. Mer-letti and A. Biggeri, Modeling mesothelioma risk associated with environmental asbestos exposure, Environ Health Per-spect 115 (2007), 1066-1071. (Pubitemid 47317074)
13. X.L. Pan, H.W. Day, W. Wang, L.A. Beckett and M.B. Schenker, Residential proximity to naturally occurring asbestos and mesothelioma risk in California, Am J Respir Crit Care Med 172 (2005), 1019-1025. (Pubitemid 41476540)
14. C. Bianchi, L. Giarelli, G. Grandi, A. Brollo, L. Ramani and C. Zuch, Latency periods in asbestos-related mesothelioma of the pleura, Eur J Cancer Prev 6 (1997), 162-166. (Pubitemid 27296781)
15. D.M. McElvenny, A.J. Darnton, M.J. Price and J.T. Hodgson, Mesothelioma mortality in Great Britain from 1968 to 2001, Occup Med (Lond) 55 (2005), 79-87. (Pubitemid 40443628)
16. H.L. Beyer, R.D. Geschwindt, C.L. Glover, L. Tran, I. Hell-strom, K.E. Hellstrom, M.C. Miller, T. Verch, W.J. Allard, H.I. Pass and N.Y. Sardesai, MESOMARK: a potential test for malignant pleural mesothelioma, Clin Chem 53 (2007), 666-672. (Pubitemid 46580236)
17. A. Cristaudo, R. Foddis, A. Vivaldi, G. Guglielmi, N. Dipalma, R. Filiberti, M. Neri, M. Ceppi, M. Paganuzzi, G.P. Ivaldi, M. Mencoboni, P.A. Canessa, N. Ambrosino, A. Chella, L. Mutti and R. Puntoni, Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer, Clin Cancer Res 13 (2007), 5076-5081. (Pubitemid 47502073)
18. B.D. Grigoriu, A. Scherpereel, P. Devos, B. Chahine, M. Le-tourneux, P. Lebailly, M. Gregoire, H. Porte, M.C. Copin and P. Lassalle, Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment, Clin Cancer Res 13 (2007), 2928-2935. (Pubitemid 46850705)
19. B.W. Robinson, J. Creaney, R. Lake, A. Nowak, A.W. Musk, N. de Klerk, P. Winzell, K.E. Hellstrom and I. Hellstrom, Mesothelin-family proteins and diagnosis of mesothelioma, Lancet 362 (2003), 1612-1616. (Pubitemid 37443528)
20. B.W. Robinson, J. Creaney, R. Lake, A. Nowak, A.W. Musk, N. de Klerk, P. Winzell, K.E. Hellstrom and I. Hellstrom, Soluble mesothelin-related protein-a blood test for mesothelioma, Lung Cancer 49(SUPPL 1) (2005), S109-S111. (Pubitemid 40798859)
21. A. Scherpereel, B. Grigoriu, M. Conti, T. Gey, M. Gregoire, M.C. Copin, P. Devos, B. Chahine, H. Porte and P. Lassalle, Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma, Am J Respir Crit Care Med 173 (2006), 1155-1160. (Pubitemid 43726897)
22. J. Creaney, D. Yeoman, A.W. Musk, N. de Klerk, S.J. Skates and B.W. Robinson, Plasma versus serum levels of osteopon-tin and mesothelin in patients with malignant mesothelioma-Which is best? Lung Cancer, Mar 11, 2011, Epub ahead of print.
23. K. Chang, L.H. Pai, J.K. Batra, I. Pastan and M.C. Willingham, Characterization of the antigen (CAK1) recognized by monoclonal antibody K1 present on ovarian cancers and normal mesothelium, Cancer Res 52 (1992), 181-186.
24. K. Chang and I. Pastan, Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers, Proc Natl Acad Sci USA 93 (1996), 136-140. (Pubitemid 26041483)
25. P.S. Chowdhury, J.L. Viner, R. Beers and I. Pastan, Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity, Proc Natl Acad Sci USA 95 (1998), 669-674. (Pubitemid 28083801)
26. T. Kojima, M. Oh-eda, K. Hattori, Y. Taniguchi, M. Tamura, N. Ochi and N. Yamaguchi, Molecular cloning and expression of megakaryocyte potentiating factor cDNA, J Biol Chem 270 (1995), 21984-21990.
27. M.D. Peake, J. Entwisle and S.G. Gray, Malignant pleu-ral mesothelioma: clinical presentation, radiological evaluation and diagnosis., in: Malignant Pleural Mesothelioma, K. O'Byrne and V. Rusch, eds, Oxford University Press, Oxford, New York, 2006, pp. 35-60.
28. N. Scholler, N. Fu, Y. Yang, Z. Ye, G.E. Goodman, K.E. Hell-strom and I. Hellstrom, Soluble member (s) of the mesothe-lin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma, Proc Natl Acad Sci USA 96 (1999), 11531-11536. (Pubitemid 29487415)
29. N.G. Ordonez, Value of mesothelin immunostaining in the diagnosis of mesothelioma, Mod Pathol 16 (2003), 192-197. (Pubitemid 36337423)
30. M. Amati, M. Tomasetti, M. Scartozzi, L. Mariotti, R. Alleva, E. Pignotti, B. Borghi, M. Valentino, M. Governa, J. Neuzil and L. Santarelli, Profiling tumor-associated markers for early detection of malignant mesothelioma: an epidemiologic study, Cancer Epidemiol Biomarkers Prev 17 (2008), 163-170. (Pubitemid 351196287)
31. B.D. Grigoriu, B. Chahine, A. Vachani, T. Gey, M. Conti, D.H. Sterman, G. Marchandise, H. Porte, S.M. Albelda and A. Scherpereel, Kinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatment, Am J Respir Crit Care Med 179 (2009), 950-954.
32. K. Tajima, M. Hirama, K. Shiomi, T. Ishiwata, M. Yoshioka, A. Iwase, S. Iwakami, M. Yamazaki, M. Toba, K. Tobino, K. Sugano, M. Ichikawa, Y. Hagiwara, K. Takahashi and O. Hino, ERC/mesothelin as a marker for chemotherapeutic response in patients with mesothelioma, Anticancer Res 28 (2008), 3933-3936.
33. P. Wheatley-Price, B. Yang, D. Patsios, D. Patel, C. Ma, W. Xu, N. Leighl, R. Feld, B.C. Cho, B. O'Sullivan, H. Roberts, M.S. Tsao, M. Tammemagi, M. Anraku, Z. Chen, M. de Perrot and G. Liu, Soluble mesothelin-related Peptide and osteopontin as markers of response in malignant mesothelioma, J Clin Oncol 28 (2010), 3316-3322.
34. J. Schneider, H. Hoffmann, H. Dienemann, F.J. Herth, M. Meister and T. Muley, Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer, J Thorac Oncol 3 (2008), 1317-1324.
35. J. Creaney, R.J. Francis, I.M. Dick, A.W. Musk, B.W. Robinson, M.J. Byrne and A.K. Nowak, Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden, Clin Cancer Res 17 (2011), 1181-1189.
36. UICC International Union Against Cancer, TNM Classification on Malignant Tumours, L. Sobin and C. Wittekind, eds, Sixth edition. New York: Wiley-Liss, 2002.
37. V. Kovac, M. Zwitter and M. Rajer, Low-dose gemcitabine in prolonged infusion and cisplatin for the treatment of malignant pleural mesothelioma. Abstract, J Thorac Oncol 6(SUPPL) (2011), S1359-S1360.
38. M. Zwitter, V. Kovac, M. Rajer, M. Vrankar and U. Smrdel, Two schedules of chemotherapy for patients with non-small cell lung cancer in poor performance status: a phase II randomized trial, Anticancer Drugs 21 (2010), 662-668.
39. A.S. Tsao, R. Mehran and J.A. Roth, Neoadjuvant and in-trapleural therapies for malignant pleural mesothelioma, Clin Lung Cancer 10 (2009), 36-41.
40. N.J. Vogelzang, J.J. Rusthoven, J. Symanowski, C. Denham, E. Kaukel, P. Ruffie, U. Gatzemeier, M. Boyer, S. Emri, C. Manegold, C. Niyikiza and P. Paoletti, Phase III study of peme-trexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma, J Clin Oncol 21 (2003), 2636-2644. (Pubitemid 46606305)
41. M.J. Byrne and A.K. Nowak, Modified RECIST criteria for assessment of response in malignant pleural mesothelioma, Ann Oncol 15 (2004), 257-260. (Pubitemid 38262625)
42. M. Dodic Fikfak, D. Kriebel, M.M. Quinn, E.A. Eisen and D.H. Wegman, A case control study of lung cancer and exposure to chrysotile and amphibole at a Slovenian asbestos-cement plant, Ann Occup Hyg 51 (2007), 261-268. (Pubitemid 47355669)
43. B.G. Ferris, Epidemiology Standardization Project (American Thoracic Society), Am Rev Respir Dis 118 (1978), 1-120.
44. M. Tomasetti and L. Santarelli, Biomarkers for early detection of malignant mesothelioma: diagnostic and therapeutic application, Cancers 2 (2010), 523-548.
45. J. Creaney, I. van Bruggen, M. Hof, A. Segal, A.W. Musk, N. de Klerk, N. Horick, S.J. Skates and B.W. Robinson, Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma, Chest 132 (2007), 1239-1246. (Pubitemid 47620999)
46. C. Bianchi and T. Bianchi, Malignant pleural mesothelioma in Italy, Indian J Occup Environ Med 13 (2009), 80-83.
47. J. Hansen, N.H. de Klerk, A.W. Musk and M.S. Hobbs, Environmental exposure to crocidolite and mesothelioma: exposure-response relationships, Am J Respir Crit Care Med 157 (1998), 69-75. (Pubitemid 28071263)
48. G.L. Ceresoli, A. Chiti, P.A. Zucali, F. Cappuzzo, F. De Vin-cenzo, R. Cavina, M. Rodari, D. Poretti, F.R. Lutman and A. Santoro, Assessment of tumor response in malignant pleural mesothelioma, Cancer Treat Rev 33 (2007), 533-541. (Pubitemid 47355343)
49. B.E. Wilcox, R.M. Subramaniam, P.J. Peller, G.L. Aughen-baugh, F.C. Nichols Iii, M.C. Aubry and J.R. Jett, Utility of integrated computed tomography-positron emission tomography for selection of operable malignant pleural mesothelioma, Clin Lung Cancer 10 (2009), 244-248.